NCT04044950 2020-09-22
A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
National Institutes of Health Clinical Center (CC)
Rutgers, The State University of New Jersey